List of Excipients in API naproxen sodium, dextromethorphan hydrobromide, guaifenesin
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing naproxen sodium, dextromethorphan hydrobromide, guaifenesin
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Reckitt Benckiser LLC | MUCINEX | naproxen sodium, dextromethorphan hydrobromide, guaifenesin | 72854-001 | CELLULOSE, MICROCRYSTALLINE | 2036-10-11 |
| Reckitt Benckiser LLC | MUCINEX | naproxen sodium, dextromethorphan hydrobromide, guaifenesin | 72854-001 | CROSCARMELLOSE SODIUM | 2036-10-11 |
| Reckitt Benckiser LLC | MUCINEX | naproxen sodium, dextromethorphan hydrobromide, guaifenesin | 72854-001 | FD&C RED NO. 40 | 2036-10-11 |
| Reckitt Benckiser LLC | MUCINEX | naproxen sodium, dextromethorphan hydrobromide, guaifenesin | 72854-001 | HYDROXYETHYL CELLULOSE | 2036-10-11 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for naproxen sodium, dextromethorphan hydrobromide, guaifenesin
Excipient focus: CELLULOSE, MICROCRYSTALLINE
naproxen sodium, dextromethorphan hydrobromide, guaifenesin drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Reckitt Benckiser LLC | naproxen sodium, dextromethorphan hydrobromide, guaifenesin | 72854-001 |
| >Company | >Ingredient | >NDC |
naproxen sodium, dextromethorphan hydrobromide, guaifenesin drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSCARMELLOSE SODIUM
naproxen sodium, dextromethorphan hydrobromide, guaifenesin drug variants containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Reckitt Benckiser LLC | naproxen sodium, dextromethorphan hydrobromide, guaifenesin | 72854-001 |
| >Company | >Ingredient | >NDC |
naproxen sodium, dextromethorphan hydrobromide, guaifenesin drug variants not containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FD&C RED NO. 40
naproxen sodium, dextromethorphan hydrobromide, guaifenesin drug variants containing FD&C RED NO. 40
| Company | Ingredient | NDC |
|---|---|---|
| Reckitt Benckiser LLC | naproxen sodium, dextromethorphan hydrobromide, guaifenesin | 72854-001 |
| >Company | >Ingredient | >NDC |
naproxen sodium, dextromethorphan hydrobromide, guaifenesin drug variants not containing FD&C RED NO. 40
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYDROXYETHYL CELLULOSE
naproxen sodium, dextromethorphan hydrobromide, guaifenesin drug variants containing HYDROXYETHYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| Reckitt Benckiser LLC | naproxen sodium, dextromethorphan hydrobromide, guaifenesin | 72854-001 |
| >Company | >Ingredient | >NDC |
naproxen sodium, dextromethorphan hydrobromide, guaifenesin drug variants not containing HYDROXYETHYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE
naproxen sodium, dextromethorphan hydrobromide, guaifenesin drug variants containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| Reckitt Benckiser LLC | naproxen sodium, dextromethorphan hydrobromide, guaifenesin | 72854-001 |
| >Company | >Ingredient | >NDC |
naproxen sodium, dextromethorphan hydrobromide, guaifenesin drug variants not containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
naproxen sodium, dextromethorphan hydrobromide, guaifenesin drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Reckitt Benckiser LLC | naproxen sodium, dextromethorphan hydrobromide, guaifenesin | 72854-001 |
| >Company | >Ingredient | >NDC |
naproxen sodium, dextromethorphan hydrobromide, guaifenesin drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL
naproxen sodium, dextromethorphan hydrobromide, guaifenesin drug variants containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Reckitt Benckiser LLC | naproxen sodium, dextromethorphan hydrobromide, guaifenesin | 72854-001 |
| >Company | >Ingredient | >NDC |
naproxen sodium, dextromethorphan hydrobromide, guaifenesin drug variants not containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM BICARBONATE
naproxen sodium, dextromethorphan hydrobromide, guaifenesin drug variants containing SODIUM BICARBONATE
| Company | Ingredient | NDC |
|---|---|---|
| Reckitt Benckiser LLC | naproxen sodium, dextromethorphan hydrobromide, guaifenesin | 72854-001 |
| >Company | >Ingredient | >NDC |
naproxen sodium, dextromethorphan hydrobromide, guaifenesin drug variants not containing SODIUM BICARBONATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM LAURYL SULFATE
naproxen sodium, dextromethorphan hydrobromide, guaifenesin drug variants containing SODIUM LAURYL SULFATE
| Company | Ingredient | NDC |
|---|---|---|
| Reckitt Benckiser LLC | naproxen sodium, dextromethorphan hydrobromide, guaifenesin | 72854-001 |
| >Company | >Ingredient | >NDC |
naproxen sodium, dextromethorphan hydrobromide, guaifenesin drug variants not containing SODIUM LAURYL SULFATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch